Prognostic value of postoperative CEA/CA19-9 positivity and elevation relative to preoperative levels in gastric cancer

Table 4 The relationship between clinicopathological characteristics and postoperative carcinoembryonic antigen and carbohydrate antigen 19-9 elevation

Variables	Post-preoperative CEA elevation			Post-preoperative CA19-9 elevation
	Yes (n = 184)	No (n = 378)	P value	Yes (n = 235)	No (n = 327)	P value
Sex			0.172			0.856
Male	119	266		160	225
Female	65	112		75	102
Age, years			0.612			0.570
< 60	84	164		107	141
≥ 60	100	214		128	186
Clinical stage			< 0.001			0.002
I, II	38	192		78	152
III	146	186		157	175
T stage			< 0.001			0.605
T1, T2	23	85		41	67
T3	29	88		48	69
T4	132	205		146	191
N stage			< 0.001			< 0.001
N0, N1	37	222		80	179
N2	47	99		62	84
N3	100	57		93	64
Differentiation			< 0.001			0.014
Moderate, good	53	206		94	165
Poor	131	172		141	162
Vascular invasion			< 0.001			0.001
Positive	92	61		81	72
Negative	92	317		154	255
Adjuvant chemotherapy			0.104			0.247
Yes	175	345		221	299
No	9	33		14	28
Recurrence pattern			< 0.001			< 0.001
No recurrence	83	286		118	251
Peritoneal recurrence	38	41		49	30
Other recurrence sites	63	51		68	46
Post-CEA			< 0.001			< 0.001
Positive	37	22		41	18
Negative	147	356		194	309
Post-CA19-9			< 0.001			0.006
Positive	24	14		24	14
Negative	160	364		211	313
PNI			< 0.001			0.072
< 49.98	128	189		143	174
≥ 49.98	56	189		92	153
PLR			< 0.001			0.436
< 138.41	76	229		123	182
≥ 138.41	108	149		112	145
LMR			0.650			0.014
< 4.32	86	169		121	134
≥ 4.32	98	209		114	193

CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; LMR: Lymphocyte to monocyte ratio; PLR: Platelet to lymphocyte ratio; PNI: Prognostic nutritional index.